These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32697072)

  • 1. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
    Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
    ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
    Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
    Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Novel BCL-X
    Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
    J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X
    Zhang X; Thummuri D; He Y; Liu X; Zhang P; Zhou D; Zheng G
    Chem Commun (Camb); 2019 Dec; 55(98):14765-14768. PubMed ID: 31754664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A selective BCL-X
    Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
    Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL.
    Nayak D; Lv D; Yuan Y; Zhang P; Hu W; Nayak A; Ruben EA; Lv Z; Sung P; Hromas R; Zheng G; Zhou D; Olsen SK
    Nat Commun; 2024 Mar; 15(1):2743. PubMed ID: 38548768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
    He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
    Negi A; Voisin-Chiret AS
    Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
    Diehl CJ; Ciulli A
    Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of PROTAC cooperative recognition for selective protein degradation.
    Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
    Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PROTAC selectively degrading Bcl-x
    Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
    Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
    [No Abstract]   [Full Text] [Related]  

  • 15. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
    He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
    Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs.
    Bricelj A; Dora Ng YL; Gobec M; Kuchta R; Hu W; Javornik Š; Rožič M; Gütschow M; Zheng G; Krönke J; Steinebach C; Sosič I
    Chemistry; 2024 Aug; 30(45):e202400430. PubMed ID: 38818652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
    Zoppi V; Hughes SJ; Maniaci C; Testa A; Gmaschitz T; Wieshofer C; Koegl M; Riching KM; Daniels DL; Spallarossa A; Ciulli A
    J Med Chem; 2019 Jan; 62(2):699-726. PubMed ID: 30540463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
    Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
    Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
    Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
    Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.